VIDAS® REFERENCE INTERVALS* LIST

TYPE OF LOW DETECTION HIGH DETECTION

RANGE PARAMETER REFERENCE CODE REFERENCE INTERVALS* PERFORMANCE UNIT TRACEABLE TO
TEST LIMIT LIMIT

SEPSIS
< 0.5 ng/mL : Low risk of severe sepsis and/or septic shock
> 2 ng/mL : High risk of severe sepsis and/or septic shock

LOWER RESPIRATORY TRACT INFECTION

< 0.10 ng/mL : Absence of bacterial infection
BACTERIAL TM Internal standard
INFECTION B.R.A.H.M.S PCT 30450 PCT Quantitative 0.05 ng/mL Antibiotic therapy is strongly discouraged N/A 200 ng/mL ng/mL
material**
0.10-0.25 ng/mL : A bacterial infection is possible
Antibiotic therapy is discouraged
0.26-0.50 ng/mL : A bacterial infection is unlikely
Antibiotic therapy is recommended
> 0.50 ng/mL : Suggestive of presence of bacterial infection
Antibiotic therapy strongly recommended

< 2 ng/ml
Internal standard
Digoxin 30603 DIG Quantitative 0.2 ng/mL N/A 5 ng/mL ng/mL
THERAPEUTIC RANGE material**
0.6–1.2 ng/ml
Internal standard
Myoglobin 30446 MYO Quantitative 5 μg/L 10 - 46 μg/L N/A 1 000 μg/L µg/L
material**

ACUTE HEART FAILURE

< 50 years old : < 450 pg/mL
EMERGENCY

From 50 to 75 years old : < 900 pg/mL pmol/L x 8.457

> 75 years old : < 1.800 pg/mL = pg/mL
Internal standard
NT-proBNP2 30458 PBN2 Quantitative 15 pg/mL For all patients : < 300 pg/mL N/A 25 000 pg/mL
CARDIAC material**
pg/mL x 0.118
= pmol/L
CHRONIC HEART FAILURE
< 75 years old : <125 pg/mL
≥ 75 years : < 450 pg/mL

2H ALGORITHM
T0 < 2 ng/L
or T0 and T2h < 6 ng/L
Internal standard
High sensitive Troponin I 415386 TNHS Quantitative 1.5 pg/mL N/A 40 000 pg/mL ng/L
material**
3H ALGORITHM
T0 < 19 ng/L with pain >6h
or T0 < 19 ng/L with pain <6h and no change at T3

To RULE-OUT VTE in LOW or MEDIUM PTP:

- conventional cut-off: < 500 μg/L RULE-OUT PE/DVT; (≥
500 μg/L continue examination).
- Age-adjusted cut-off > 50y.o. < Age x 10 μg/L
Internal standard
D-Dimer ExclusionTM II 30455 DEX2 Quantitative 45 ng/mL N/A 10 000 ng/mL ng/mL
material**
For HERDOO2 rule for Women:
- VIDAS® D-DIMER EXCLUSION™ II <250 μg/L.
VENOUS THROMBO- HER. Obesity and age criteria must be evaluated to follow
EMBOLISM / the rule.
COAGULATION
Protein C 30115 PC Quantitative 0.01 >70% N/A 1.2 % WHO 1st IS 86/622

O BLOOD GROUP
52% to 154%
WHO International
vWF 30436 VWF Quantitative 0.01 N/A 1.2 %
Standard (91/666)
NON O BLOOD GROUP
60 - 200%

Negative: <15 mIU/mL WHO 1st reference

Sensitivity(a)*: 100% (CI 95%: 99.4% - 100%)
preparation Hepatitis A
Anti-HAV Total 30312 HAVT Quantitative 15 mIU/mL Borderline positive: > 15 - <20 mIU/mL Specificity(a)*: 100% (CI 95%: 99.2% - 100%) 400 mIU/mL mIU/mL
Immunoglobulin (100
Positive: > 20 mIU/mL * 1136 blood donor samples studied
IU/mL)

Negative: i < 0.4 Sensitivity(a): 98.0% (205 acute hepatitis A samples

tested) Internal standard
HAV IgM 30307 HAVM Qualitative N/A Equivocal: i > 0.4 to i < 0.5 Specificity(a): 99.4% (544 blood donor samples
N/A N/A
material**
Positive: i > 0.5 tested)

Negative: < 8 mIU/mL Sensitivity(b)*: 99% (CI 95%: 98.2% - 99.5%)

Anti-HBs Total II 30318 AHBS Quantitative 3 mIU/mL Equivocal: > 8 - < 12 mIU/mL Specificity(b)*: 99% (CI 95%: 98.1% - 99.5%) 500 mIU/mL mIU/mL WHO 2nd IRP 07/164
Positive: > 12 mIU/mL * 2110 samples studied

HBS
Negative: i < 0.13 Analytical sensitivity* : 0.075 IU/mL (HBS) 0.05
Positive: i > 0.13 IU/mL (HBL)
Detectability on 506 positive samples : 100% (CI International standard
HBs Ag Ultra 30315 HBS/HBL Qualitative N/A N/A N/A
95%: 99.22% - 100%) NIBSC 00/0588
HBL Relative specificity on 5059 blood donors samples
Négative : i < 0.10 (HBS/HBL): 100% (CI 95%: 99.87% - 100%)
Positive : i > 0.10

N/A
N/A True positive: > 50% of neutralization N/A N/A
HBs Ag Ultra Confirmation 30317 P24 Confirmation N/A N/A
confirmation test Negative: < 50% of neutralization confirmation test confirmation test
test
HEPATITIS
Negative: < 5 PEIU/mL
Sensitivity(a): 100% (CI 95%: 97.98% - 100%) PEI (Paul Erlich Institut)
HBc IgM II 30439 HBCM Quantitative 5 PEIU/mL Equivocal: > 5 to < 10 PEIU/mL Specificity(a): 99.67% (IC 95%: 98.77% - 99.91%)
200 PEIU/mL PEIU/mL
N°84
Positive: > 10 PEIU/mL

Negative: i > 1.4

Sensitivity(a): 99.56% (CI 95%: 97.46% - 99.9%) Internal standard
Anti-HBc Total II 30314 HBCT Qualitative N/A Equivocal: i > 1.0 to i < 1.4 Specificity(a): 99.94% (CI 95%: 99.82% - 99.98%)
N/A N/A
material**
Positive: i < 1.0
INFECTIOUS DISEASES

Negative: i < 1 Sensitivity(b): 100% (CI 95%: 99.16% - 100%) Internal standard
Anti-HCV 30308 HCV Qualitative N/A N/A N/A
Positive: i > 1 Specificity(b): 99.5% (CI 95%: 97.25% - 99.5%) material**

Positive agreement*: 96.67% (CI 95%: 92.39% -

98.91%)
Negative: < 0.56 U/mL Internal standard
Anti-HEV IgG 418116 HEVG Quantitative 0.1 U/mL Negative agreement*: 96.42% (CI 95%: 93.68% - 10 U/mL U/mL
Positive: > 0.56 U/mL material**
98.20%)
*Immunocompetent population

Negative: i < 0.1 Analytical sensitivity : 0.25 PEI U/mL (Paul Erlich
Institute Unit)
Positive: i > 0.1 Sensitivity(a): 98.1% (CI 95%: 95.1% - 97.3%)
Specificity(a) : 100% ( CI 95%: 97.6% - 100%)
HBE N/A Internal standard
HBe/Anti-HBe 30305 Qualitative N/A N/A
HBET Negative: i > 0.5 N/A material**
Equivocal: i > 0.4 to i < 0.5 Analytical sensitivity : 0.03 PEI U/mL (Paul Erlich
Institute Unit)
Positive: i < 0.4 Sensitivity(a): 98.65% (CI 95%: 96.52% - 99.48%)
Specificity(a): 99.49% (CI 95%: 98.47% - 99.83%)

Negative: i < 0.25 Sensitivity(b): 100% (CI 95%: 99.29% - 100%) N/A Internal standard
HIV DUO Ultra 30443 HIV5 Qualitative N/A N/A
Positive: i > 0.25 Specificity: 99.88% (CI 95%: 99.73% - 99.95%) N/A material**

Negative: i < 0.25 Sensitivity(b): 100% (CI 95%: 99.29% - 100%) Internal standard
HIV DUO Quick 30447 HIV6 Qualitative N/A N/A N/A
Positive: i > 0.25 Specificity: 99.88% (CI 95%: 99.74% - 99.95%) material**

Analytical sensitivity: 0.75 IU/mL (IS)

HIV Analytical sensitivity: 3.1 pg /mL (range point of
Negative: < 3 pg/mL French reference HIV-1 genotype B)
international standard
HIV P24 II 30117 P24 Quantitative 3 pg/mL Equivocal: > 3 to < 5 pg/mL Sensitivity: 124 HIV-1 group M samples tested. all 400 pg/mL pg/mL
NIBSC 90/636
Positive: > 5 pg/mL were detected
Specificity*: 100.00% (CI 95%: 98.68% - 100%)
*Hospitalized patients
N/A
N/A Positive : P ≥ 60% N/A N/A
HIV P24 II 30444 - confirmation N/A N/A
confirmation test Negative : P < 60% confirmation test confirmation test
test

Negative: i < 4 AU/mL

Sensitivity: 98.26% (CI 95%: 94.90% - 99.42%) Internal standard
CMV IgG 30204 CMVG Quantitative 4 AU/mL Equivocal: i > 4 to < 6 AU/mL Specificity: 100% (CI 95%: 96.15% - 100%)
400 AU/mL AU/mL
material**
Positive: i > 6 AU/mL

Low avidity: i < 0.40 (strong indication of primary infection

less than 3 months) Diagnostic agreement for primary infection less than
3 months: 97.3% ( CI95%: 92.2% - 99.4%)
CMV IgG Avidity II 413557 CMVA Qualitative N/A Borderline avidity: i > 0.4 to < 0.65 Diagnostic agreement for primary infection more than
N/A N/A N/A
High avidity: i > 0.65 (strong indication of primary infection 3 months: 97.8% ( CI95%: 95.5% - 99.1%)
more than 3 months)

Negative: i < 0.7

Sensitivity: 90.24% (CI 95%: 76.87% - 97.28%) Internal standard
CMV IgM 30205 CMVM Qualitative N/A Equivocal: i > 0.7 to i < 0.9 Specificity: 99.41% (CI 95%: 96.65% - 99.90%)
N/A N/A
material**
Positive: i > 0.9

Negative: i < 10 IU/mL

Sensitivity(a): 97.87% (CI 95%: 94.57% - 99.18%)
Rub IgG II 30221 RBG Quantitative 10 IU/mL Equivocal: i > 10 to < 15 IU/mL Specificity(a): 99.26% (CI 95%: 95.81% - 99.87%)
400 IU/mL IU/mL WHO 1st IS RUBI-1-94
Positive:i >15 IU/mL

ToRC Negative: i < 0.80

Sensitivity: 100.00% (CI 95%: 90.75% - 100.00%) Internal standard
Rub IgM 30214 RBM Qualitative N/A Equivocal: i > 0.80 to i < 1.20 Specificity: 98.35% (CI 95%: 95.77% - 99.37%)
N/A N/A
material**
Positive: i > V1
1.20- May 2020 1
 VIDAS® REFERENCE INTERVALS* LIST
ToRC
TYPE OF LOW DETECTION HIGH DETECTION
RANGE PARAMETER REFERENCE CODE REFERENCE INTERVALS* PERFORMANCE UNIT TRACEABLE TO
TEST LIMIT LIMIT

Negative: i < 4 IU/mL

Sensitivity: 99.65% (CI 95%: 98.75% - 99.76%)
Toxo IgG II 30210 TXG Quantitative 4 IU/mL Equivocal: i > 4 to < 8 IU/mL Specificity: 99.92% (CI 95%: 99.58% - 100%)
300 IU/mL IU/mL WHO 2nd IS
Positive: i > 8 IU/mL

Low IgG avidity : i < 0.200 Performances*: 100% (CI 95%: 98.06% - 100%)
Borderline IgG avidity: i > 0.200 to < 0.300 *none of the samples from individuals infected by
Toxo IgG Avidity 30222 TXGA Qualitative N/A N/A N/A N/A
High IgG avidity: i > 0.300 (strong indication of primary Toxoplasma gondii less than 4 months ago had an
infection dating back more than 4 months) avidity > 0.300

Negative: i < 0.55 Sensitivity(a)*: 96.00% (CI 95%: 91.43% - 98.18%)

Internal standard
Toxo IgM 30202 TXM Qualitative N/A Equivocal: i > 0.55 and i < 0.65 Specificity(b): 99.25% (CI 95%: 98.66% - 99.59%) N/A N/A
material**
Positive: i > 0.65 *Acquired toxoplasmosis

Negative: i > 1.6 Sensitivity: 99.37% (CI 95%: 98.68% - 99.70%) Internal standard
Toxo Competition 30211 TXC Qualitative N/A N/A
Positive: i < 1.6 Specificity: 99.34% (CI 95%: 98.54% - 99.70%) material**

Negative: i < 0.1 Sensitivity: 95.8% (CI 95%: 92.8% - 97.7%) Internal standard
C. difficile GDH 30125 GDH Qualitative N/A N/A N/A
Positive: i > 0.1 Specificity: 90.0% (CI 95%: 98.5% - 99.5% material**

Negative: i < 0.13

Sensitivity: 88.3% (CI 95%: 81.2% - 93.5%) Internal standard
INFECTIOUS DISEASES

C. difficile Toxin A & B 30118 CDAB Qualitative N/A Equivocal: i > 0.13 to i < 0.37 Specificity: 99.8% (CI 95%: 99.2% - 99.9%)
N/A N/A
material**
Positive: i > 0.37

Negative: i < 0.09

Sensitivity: 97.10% (CI 95%: 94.05% - 98.61%) Internal standard
EBV EBNA IgG 30235 EBNA Qualitative N/A Equivocal: i > 0.10 to i < 0.20 Specificity: 97.98% (CI 95%: 95.84% - 99.03%)
N/A N/A
material**
Positive: i > 0.21

Negative: i < 0.09

Sensitivity: 96.42% (CI 95%: 94.02% - 97.88%) Internal standard
EBV VCA/EA IgG 30236 VCAG Qualitative N/A Equivocal: i > 0.10 and i < 0.20 Specificity: 100% (CI 95%: 97.63% - 100%)
N/A N/A
material**
Positive: i > 0.21

Negative: i < 0.11

Sensitivity: 88.40% (CI 95%: 82.79% - 92.35%) Internal standard
EBV VCA IgM 30237 VCAM Qualitative N/A Equivocal: i > 0.12 to i < 0.18 Specificity: 97.87% (CI 95%: 95.96% - 98.89%)
N/A N/A
material**
Positive: i > 0.19

Negative: i < 0.75

Sensitivity(b): 98.10% (CI 95%: 93.12% - 99.77%) Internal standard
H.pylori IgG 30192 HPY Qualitative N/A Equivocal: i > 0.75 to i < 1.00 Specificity(b): 90.82% (CI 95%: 83.28% - 95.75%)
N/A N/A
material**
Positive: i > 1.00

ADDITIONAL IgG Sensitivity: > 51% (Erythema migrans) >90 %

SEROLOGIES (Neuroborreliosis) > 96 % (Arthritis/acrodermatitis)
IgG + IgM Combined sensitivity: > 76% (Erythema
Negative: i < 0.20 Internal standard
Lyme IgG 30320 LYG Qualitative N/A migrans) >90 % (Neuroborreliosis) > 96 % N/A N/A
Positive: i > 0.20 material**
(Arthritis/acrodermatitis)
Specificity*: 99.3% (CI 95%: 97.4% - 99.9%)
* Low prevalence area

IgM Sensitivity: > 47% (Erythema migrans) > 35 %

(Neuroborreliosis) > 37 % (Arthritis/acrodermatitis)
Negative: i < 0.20 IgG + IgM Combined sensitivity: > 76% (Erythema
Internal standard
Lyme IgM 30319 LYM Qualitative N/A Equivocal: i > 0.20 to i < 0.32 migrans) >90 % (Neuroborreliosis) > 96 % N/A N/A
material**
Positive: i > 0.32 (Arthritis/acrodermatitis)
Specificity*: 96.3% (CI 95%: 93.3% - 99.9%)
* Low prevalence area

Negative: i < 0.50 Sensitivity(a)*: 99.0% (CI 95%: 93.3% - 99.7%)

Internal standard
Measles IgG 30219 MSG Qualitative N/A Equivocal: i > 0.50 to i < 0.70 Specificity(a)*: 96.5% (CI 95%: 87.9% - 99.6%) N/A N/A
material**
Positive: i > 0.70 *versus EIA+IFA

Negative: i < 0.35 Sensitivity(a)*: 98.5% (CI 95%: 95.5% - 99.5%)

Internal standard
Mumps IgG 30218 MPG Qualitative N/A Equivocal: i > 0.35 to i < 0.50 Specificity(a)*: 93.1% (CI 95%: 77.2% - 99.2%) N/A N/A
material**
Positive: i > 0.50 * versus EIA+IFA

Negative: i < 0.60 Relative sensitivity*: 99.7% (CI 95%: 98.2% - 99.9%)
Internal standard
Varicella-Zoster IgG 30217 VZG Qualitative N/A Equivocal: i > 0.60 to i < 0.90 Relative specificity*: 97.6% (CI 95%: 87.1% - 99.9%) N/A N/A
material**
Positive: i > 0.90 *versus Latex agglutination+IFA

> 7 µIU/mL : Hypothyroid

TSH 30400 TSH Quantitative 0.05 µIU/mL 0.25 - 5 µIU/mL : Euthyroid N/A 60 µIU/mL µIU/mL WHO 2nd IRP 80/558
< 0.15 µIU/mL : Hyperthyroid

> 4.7 µIU/mL : Hypothyroid

TSH3 30441 TSH3 Quantitative 0.005 µIU/mL 0.27 - 4.7 µIU/mL : Euthyroid N/A 100 µIU/mL µIU/mL WHO 2nd IRP 80/558
< 0.27 µIU/mL : Hyperthyroid
pmol/L x 0.651
= pg/mL Internal standard
FT3 30402 FT3 Quantitative 0.7 pmol/L 4 - 8.3 pmol/L N/A 45 pmol/L
pg/mL x 1.54 material**
= pmol/L
pmol/L x 0.777
= pg/mL Internal standard
FT4N 30459 FT4N Quantitative 1 pmol/L 9 - 20 pmol/L N/A 100 pmol/L
pg/mL x 1.29 material**
THYROID
= pmol/L
nmol/L x 0.651
= µg/L Internal standard
T3 30403 T3 Quantitative 0.4 nmol/L 0.92 - 2.33 nmol/L N/A 9 nmol/L
µg/L x 1.54 material**
= nmol/L
nmol/L x 0.777
= µg/L Internal standard
T4 30404 T4 Quantitative 6 nmol/L 60 - 120 nmol/L N/A 320 nmol/L
µg/L x 1.29 material**
= nmol/L

Anti-Tg 30462 ATG Quantitative 6.4 IU/mL < 18.00 IU/mL N/A 800 IU/mL IU/mL WHO 66/387
IMMUNOCHEMISTRY

Anti-TPO 30461 ATPO Quantitative 0.8 IU/mL < 8.00 IU/mL N/A 1 000 IU/mL IU/mL WHO 65/093

WOMEN
From 12 to 17 years old : 1.57 - 7.60 ng/mL
From 18 to 24 years old : 2.15 - 8.40 ng/mL pmol/L x 0.14 Internal standard
= ng/ml material**
AMH 417011 AMH Quantitative 0.02 ng/mL From 25 to 29 years old : 1.56 - 8.76 ng/mL N/A 9 ng/mL
ng/mL x 7.14 [10th percentile - 90th
From 30 to 34 years old : 1.19 - 7.00 ng/mL = pmol/L percentile]
From 35 to 39 years old : 0.36 - 5.15 ng/mL
From 40 to 44 years old : 0.17 - 3.84 ng/mL
MEN
< 62 pg/mL
pg/mL x 3.7 ->
WOMEN pmol/L
Estradiol II 30431 E2II Quantitative 9 pg/mL N/A 3000 pg/mL ID-GCMS
Follicular phase : 18-147 pg/mL pmol/L x 0.272 ->
Pre-ovulatory : 93 – 573 pg/mL pg/mL
Luteal Phase : 43 – 214 pg/mL
Menopausal Women : < 58 pg/mL

MEN
1.7 - 12 mIU/mL

WOMEN
FSH 30407 FSH Quantitative 0.1 mIU/mL 1st half of the follicular phase (J-1-J11) : 3.9 - 12 mIU/mL N/A 110 mIU/mL mIU/mL WHO 2nd IRP 78/549
2nd half of the follicular phase (J6-J12) : 2.9 - 9.0 mIU/mL
Ovulation day (J14) : 6.3 - 24 mIU/mL
Luteal phase (J17 - J28): 1.5 - 7.0 mIU/mL
Menopausal women : 17 - 95 mIU/mL

MEN
1.1 - 7.0 mIU/mL

WOMEN
LH 30406 LH Quantitative 0.1 mIU/mL 1st half of the follicular phase (J-1-J11) : 1.5 - 8.0 mIU/mL N/A 100 mIU/mL mIU/mL WHO 2nd IS 80/552
2nd half of the follicular phase (J6-J12) : 2.0 -8.0 mIU/mL
Ovulation day (J14) : 9.6 - 80 mIU/mL
HORMONES / FERTILITY Luteal phase (J17 - J28): 0.2 - 6.5 mIU/mL
Menopausal women : 8.0 - 33 mIU/mL

WOMEN
HCG 30405 HCG Quantitative 2 mIU/mL Normal menstruating : < 5 mIU/mL N/A 1 500 mIU/mL mIU/mL WHO 1st IRP 75/537
Menopausal : < 10 mIU/mL

MEN 1 ng 1st IRP

3 - 25 ng/mL = 32 uUI
1 ng 3rd IS = 21
Prolactin 30410 PRL Quantitative 0.5 ng/mL N/A 200 ng/mL uUI WHO 3rd IS 84/500
WOMEN 1 ng/mL 3rd IS
Normal menstruating : 5 - 35 ng/mL = 1,524 ng/mL 1st
Menopausal : 5 - 35 ng/mL IRP

V1 - May 2020 2
 VIDAS® REFERENCE INTERVALS* LIST
TYPE OF LOW DETECTION HIGH DETECTION
RANGE PARAMETER REFERENCE CODE REFERENCE INTERVALS* PERFORMANCE UNIT TRACEABLE TO
TEST LIMIT LIMIT

MEN
< 0.25 - 0.56 ng/mL
ng/mL x 3.1796 ->
WOMEN nmol/L
Progesterone 30409 PRG Quantitative 0.25 ng/mL N/A 80 ng/mL ID-GCMS
Follicular phase : < 0.25 – 0.54 ng/ml nmol/L x 0.3145 ->
Luteal phase : 1.5 – 20.0 ng/ml ng/mL
Ovulation (J-1 to J+2) : 0.25 – 6.22 ng/ml
Menopause : < 0.41 ng/ml

MEN
3.0 - 10.6 ng/mL nmol/L x 0.288 ->
ID-GCMS
ng/mL
Testosterone II 414320 TES2 Quantitative 0.05 ng/mL N/A 13.50 ng/mL [5th percentile - 95th
WOMEN ng/mL x 3.47 ->
percentile]
From 19 to 50 years old : 0.23 - 0.73 ng/mL nmol/L
> 50 years old : 0.14 - 0.68 ng/mL

Morning
60 - 285 ng/mL nmol/L x 0.362 ->
ng/mL
Cortisol S 30451 CORS Quantitative 2 ng/mL N/A 650 ng/mL ID-GCMS
ng/mL x 2.76 ->
Afternoon nmol/L
40 - 150 ng/mL
IMMUNOCHEMISTRY

< 40 years old : 0.21 - 1.72 ng/mL

From 40 to 49 years old : 0.27 - 2.19 ng/mL
Internal standard
TPSA 30428 TPSA Quantitative 0.07 ng/mL From 50 to 59 years old : 0.27 - 3.42 ng/mL N/A 100 ng/mL ng/mL
material**
From 60 to 69 years old : 0.22 - 6.16 ng/mL
> 69 years old : 0.21 - 6.77 ng/mL
Internal standard
FPSA 30440 FPSA Quantitative 0.05 ng/mL FPSA/TPSA ratio < 18 % N/A 10 ng/mL ng/mL
material**

NON SMOKING
≤ 2.30 ng/mL
Internal standard
CEA (S) 30453 CEAS Quantitative 0.5 ng/mL N/A 200 ng/mL ng/mL
material**
SMOKING
≤ 4.10 ng/mL
MEN ng/mL x 0.826 ->
TUMOUR MARKERS
3.12 - 4.35 ng/Ml IU/mL
AFP 30413 AFP Quantitative 0.5 IU/mL N/A 400 IU/mL WHO 1st IRP 72/225
IU/mL x 1.21 ->
PREGNANT WOMEN => see package inserts ng/mL

Internal standard
CA 15-3 30429 CA 15-3 Quantitative 2 U/mL ≤ 30 U/mL N/A 400 U/mL U/mL
material**
Internal standard
CA 19-9TM 30427 CA 19-9 Quantitative 3 U/mL ≤ 37 U/mL N/A 500 U/mL U/mL
material**
Internal standard
CA 125TM 30426 CA 125 Quantitative 4 U/mL ≤ 35 U/mL N/A 600 U/mL U/mL
material**

SERUM
0.81 - 2.19 mg/L
β2 Microglobulin 30420 β2M Quantitative 0.004 mg/L N/A 4 mg/L mg/L WHO 2nd IRP 75/502
URINE
0.00 - 0.15 mg/L

ALLERGY Total IgE 30419 IGE Quantitative 0.5 kIU/L < 120 KIU/L N/A 1000 kIU/L kIU/L

PTH (1-84) 422010 PTH Quantitative 4.0 pg/mL 9.2 - 44.6 pg/mL N/A 1 500 pg/mL pg/mL WHO IS 95/646

< 20 ng/mL : Deficient

20 - 29 ng/mL : Insufficient Internal standard
25 OH Vitamin D Total 30463 VITD Quantitative 8.1 ng/mL N/A 126 ng/mL ng/mL
30 - 100 ng/mL : Sufficient material**
BONE & MINERAL > 100 ng/mL : Potential toxicity
METABOLISM
MEN
70 - 435 ng/mL
Internal standard
Ferritin 30411 FER Quantitative 1.5 ng/mL N/A 1 200 ng/mL kIU/L
WOMEN material**
non-menopausal : 10 - 160 ng/mL
menopausal : 25 - 280 ng/mL

The information in this document is given as an aid to result interpretation by the clinician based on patient history.
bioMérieux assumes no responsability or liability for any diagnosis established or treatment prescribed by the clinician.
Always consult a medical director, a physician, or other health provider regarding processes and/or protocol for
diagnosis and treatment of a medical condition. It is recommended that each laboratory establish its own reference
reference values from a rigorously selected population. All the information in this document comes from VIDAS CE Marking
package inserts at May 2020.
*The term Reference Intervals is used for quantitative tests. For qualitative tests, the data in this column are the results interpretation of the CE package insert.
Refer to the package inserts for the Confidence Intervals.

V1 - May 2020 3